Editorial
doi: 10.1002/ana.26167.
Epub 2021 Aug 10.
Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease
Affiliations
- PMID: 34278596
- DOI: 10.1002/ana.26167
Item in Clipboard
Editorial
Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease
Ann Neurol.
2021 Sep.
No abstract available
Comment in
-
Thinking beyond the Aducanumab Controversy.Ann Neurol. 2021 Dec;90(6):1003-1004. doi: 10.1002/ana.26252. Epub 2021 Nov 5. Ann Neurol. 2021. PMID: 34687081 No abstract available.
-
Reply to "Letter Concerning Moghavem, Henderson, and Greicius Article".Ann Neurol. 2021 Dec;90(6):1006-1007. doi: 10.1002/ana.26255. Epub 2021 Nov 5. Ann Neurol. 2021. PMID: 34687242 No abstract available.
-
Letter Concerning Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease by Moghavem, Henderson, and Greicius.Ann Neurol. 2021 Dec;90(6):1004-1006. doi: 10.1002/ana.26254. Epub 2021 Nov 5. Ann Neurol. 2021. PMID: 34687454 No abstract available.
Similar articles
-
Medicare Coverage of Aducanumab - Implications for State Budgets.N Engl J Med. 2021 Nov 25;385(22):2019-2021. doi: 10.1056/NEJMp2115297. Epub 2021 Nov 20. N Engl J Med. 2021. PMID: 34797617 No abstract available.
-
Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?JAMA. 2021 Aug 3;326(5):383-384. doi: 10.1001/jama.2021.11768. JAMA. 2021. PMID: 34279572 No abstract available.
-
Medicare's National Coverage Determination for Aducanumab - A One-Off or a Pragmatic Path Forward?N Engl J Med. 2022 Oct 27;387(17):1539-1541. doi: 10.1056/NEJMp2210198. Epub 2022 Oct 22. N Engl J Med. 2022. PMID: 36301560 No abstract available.
-
Possible Consequences of the Approval of a Disease-Modifying Therapy for Alzheimer Disease.JAMA Neurol. 2021 Feb 1;78(2):141-142. doi: 10.1001/jamaneurol.2020.4478. JAMA Neurol. 2021. PMID: 33252672 Review. No abstract available.
-
Aducanumab and the FDA - where are we now?Nat Rev Neurol. 2021 Mar;17(3):129-130. doi: 10.1038/s41582-020-00454-9. Nat Rev Neurol. 2021. PMID: 33442064 Review. No abstract available.
Cited by
-
Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer's Disease in Spain.Alzheimers Res Ther. 2022 Nov 12;14(1):171. doi: 10.1186/s13195-022-01111-7. Alzheimers Res Ther. 2022. PMID: 36371267 Free PMC article.
-
The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All.J Alzheimers Dis. 2022;90(3):953-962. doi: 10.3233/JAD-220458. J Alzheimers Dis. 2022. PMID: 35938255 Free PMC article.
-
Aducanumab: What about the Patient?Ann Neurol. 2021 Sep;90(3):334-335. doi: 10.1002/ana.26181. Epub 2021 Aug 7. Ann Neurol. 2021. PMID: 34322904 Free PMC article. No abstract available.
References
-
- Biogen, Inc. Aduhelm (aducanumab) [package insert]. U.S. Food and Drug Administration website. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf. Accessed June 24, 2021.
-
- Centers for Medicare & Medicaid Services (CMS), HHS. Medicare program; revised process for making Medicare National Coverage Determinations final rule. Fed Regist 2003;68:55528-55539.
-
- Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-1562.
-
- Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:322-333.
-
- Fleisher AS, Joshi AD, Sundell KL, et al. Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. Alzheimers Dement 2017;10:1117-1124.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
